Methods of treating respiratory syncytial virus infections
Compositions and methods for the treatment of respiratory syncytial virus infections are provided.
1. A pharmaceutically acceptable aerosol for the treatment of a lung condition in a subject, consisting of droplets of a solution consisting of (i) from about 4% to about 6% by weight of cromolyn sodium and (ii) an osmolarity adjusting agent consisting of (a) between 0.1% and 0.5% by weight of sodium chloride, inclusive of the endpoints, and (b) optionally salts of ethylenediaminetetraacetic acid (EDTA), and (iii) water; wherein the aerosol has a respirable fraction (≤3.3 μm) as measured by USP <1601> of between about 30% and about 95%, inclusive of the endpoints, and wherein the treatment of the lung condition in the subject is achieved via delivery of a therapeutically effective amount of cromolyn sodium to the lungs of the subject by the subject orally inhaling the pharmaceutically acceptable aerosol.
2. The pharmaceutically acceptable aerosol of claim 1 , wherein the salts of EDTA comprise sodium EDTA.
3. The pharmaceutically acceptable aerosol of claim 1 , wherein the solution contains from about 5 mg to about 80 mg of cromolyn sodium.
4. The pharmaceutically acceptable aerosol of claim 1 , wherein the solution contains from about 36 mg to about 44 mg of cromolyn sodium.
5. The pharmaceutically acceptable aerosol of claim 1 , wherein the aerosol has a respirable fraction (≤5 μm) as measured by USP <1601> of between about 75% and about 95%, inclusive of the endpoints.
6. The pharmaceutically acceptable aerosol of claim 1 , wherein the sodium chloride is at a concentration of between 0.1% to 0.2% by weight, inclusive of the endpoints.
7. A pharmaceutically acceptable aerosol for delivery of a therapeutically effective amount of cromolyn sodium to the lungs of a subject, wherein the pharmaceutically acceptable aerosol is a nebulized solution consisting of (i) from about 4% to about 6% by weight of cromolyn sodium, (ii) between 0.1% and 0.5% by weight of sodium chloride, inclusive of the endpoints, (iii) a salt of EDTA, and (iv) water, wherein the delivery of a therapeutically effective amount of cromolyn sodium to the lungs of the subject is achieved by the subject orally inhaling the pharmaceutically acceptable aerosol.
8. The pharmaceutically acceptable aerosol of claim 7 , wherein the salt of EDTA is sodium EDTA.
9. The pharmaceutically acceptable aerosol of claim 7 , wherein the solution contains from about 5 mg to about 80 mg of cromolyn sodium.
10. The pharmaceutically acceptable aerosol of claim 7 , wherein the solution contains from about 36 mg to about 44 mg of cromolyn sodium.
11. The pharmaceutically acceptable aerosol of claim 7 , wherein the aerosol has a respirable fraction (≤3.3 μm) as measured by USP <1601> of between about 30% and about 95%, inclusive of the endpoints.
12. The pharmaceutically acceptable aerosol of claim 7 , wherein the aerosol has a respirable fraction (≤3.3 μm) as measured by USP <1601> of between about 30% and about 95%, inclusive of the endpoints, and a respirable fraction (≤5 μm) as measured by USP <1601> of between about 75% and about 95%, inclusive of the endpoints.
13. The pharmaceutically acceptable aerosol of claim 7 , wherein the sodium chloride is at a concentration of between 0.1% to 0.2% by weight, inclusive of the endpoints.
14. A method of treating a lung condition in a subject, comprising administering a pharmaceutically acceptable aerosol to the subject by oral inhalation, the pharmaceutically acceptable aerosol consisting of droplets of a solution consisting of (i) from about 4% to about 6% by weight of cromolyn sodium, (ii) between 0.1% and 0.5% by weight of sodium chloride, inclusive of the endpoints, (iii) optionally salts of ethylenediaminetetraacetic acid (EDTA), and (iv) water; wherein the aerosol has a respirable fraction (≤3.3 μm) as measured by USP <1601> of between about 30% and about 95%, inclusive of the endpoints.
15. The method of claim 14 , wherein the salts of EDTA comprise sodium EDTA.
16. The method of claim 14 , wherein the solution contains from about 5 mg to about 80 mg of cromolyn sodium.
17. The method of claim 14 , wherein the solution contains about from about 36 mg to about 44 mg of cromolyn sodium.
18. The method of claim 14 , wherein the aerosol has a respirable fraction (≤3.3 μm) as measured by USP <1601> of between about 30% and about 95%, inclusive of the endpoints.
19. The method of claim 14 , wherein the aerosol has a respirable fraction (≤5 μm) as measured by USP <1601> of between about 75% and about 95%, inclusive of the endpoints.
20. The method of claim 16 , wherein the aerosol has a further respirable fraction (≤5 μm) as measured by USP <1601> of between about 75% and about 95%, inclusive of the endpoints.
21. The method of claim 14 , wherein the sodium chloride is at a concentration of between 0.1% to 0.2% by weight, inclusive of the endpoints.